

**LSE: AIM release**  
**5 August, 2003**

**MARSHALL EDWARDS INC. APPOINTS NEW DIRECTOR**

(Washington DC: August 4 2003) The Board of Marshall Edwards Inc. (MEI) has appointed Mr Stephen Breckenridge as a non-executive director.

Mr Breckenridge was a partner of KPMG for 24 years, in corporate taxation, specialising in transfer pricing.

Since 2001, Mr Breckenridge has been principal of his own practice focusing on the provision of independent tax and management advice to multi-national corporations and SMEs.

Mr Breckenridge holds a Masters degree in Tax from the University of Sydney, is a Fellow of the Institute of Chartered Accountants and the Taxation Institute of Australia.

The chairman of MEI, Dr Graham Kelly, said Mr Breckenridge's international business experience would be of significant value as the Company began commercialising drugs, including the in-licensed novel anti-cancer compound phenoxodiol, now in phase II clinical trials.

MEI, is incorporated in the US State of Delaware and its shares are traded on the London Stock Exchange's, Alternate Investment Market (AIM).

The Company is 95 per cent owned by Novogen Limited (NASDAQ: NVGN), with the balance of the shareholding held by international institutions and investors who participated in a US\$10 million capital raising, when the Company listed in May 2002.

Mr Breckenridge joins a board comprising chairman Dr Graham Kelly, non-executive directors Mr Philip Johnston, Professor Paul Nestel AO and Professor David de Kretser AO, and executive director and President, Mr Christopher Naughton.

More information on phenoxodiol and on the Company can be found at [www.marshalledwardsInc.com](http://www.marshalledwardsInc.com) and [www.novogen.com](http://www.novogen.com).

---

<b>ISSUED FOR</b>	<b>:</b>	<b>MARSHALL EDWARDS INC</b>
<b>FOR FURTHER INFORMATION</b>	<b>:</b>	<b>CHRISTOPHER NAUGHTON, PRESIDENT</b> <b>TEL +61 2 8877 6196</b> <b>DAVID SHEON TEL +1 202 518 6384</b>